RDHL
RedHill Biopharma Ltd.
Drug Manufacturers - Specialty & Generic
Market Cap$5M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RDHL vs CMPX
Revenue, margins, valuation, and 5-year total return — side by side.
CMPX
Compass Therapeutics, Inc.
Biotechnology
Market Cap$253M
5Y Perf.-73.9%
RDHL vs CMPX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RDHL | CMPX |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $5M | $253M |
| Revenue (TTM) | $10M | $0.00 |
| Net Income (TTM) | $-9M | $-68M |
| Gross Margin | 64.5% | — |
| Operating Margin | -110.4% | — |
| Total Debt | $356K | $10M |
| Cash & Equiv. | $5M | $31M |
RDHL vs CMPX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RDHL
CMPX
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| RedHill Biopharma L… (RDHL) | 100 | 0.0 | -100.0% |
| Compass Therapeutic… (CMPX) | 100 | 26.1 | -73.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RDHL vs CMPX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CMPX leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. RedHill Biopharma Ltd. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
RDHL
RedHill Biopharma Ltd.
The Growth Play
RDHL is the clearest fit if your priority is growth exposure.
- Rev growth 23.2%, EPS growth -115.2%, 3Y rev CAGR -54.6%
- 23.2% revenue growth vs CMPX's -100.0%
Best for: growth exposure
CMPX
Compass Therapeutics, Inc.
The Income Pick
CMPX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.22
- -78.5% 10Y total return vs RDHL's -100.0%
- Lower volatility, beta 1.22, Low D/E 5.0%, current ratio 15.02x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RDHL | 23.2% revenue growth vs CMPX's -100.0% |
| Quality / Margins | CMPX | 2.9% margin vs RDHL's -97.5% |
| Stability / Safety | CMPX | Beta 1.22 vs RDHL's 1.30 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CMPX | +2.8% vs RDHL's -49.0% |
| Efficiency (ROA) | CMPX | -35.3% ROA vs RDHL's -51.1% |
RDHL vs CMPX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
RDHL vs CMPX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCMPXLAGGINGRDHL
RDHLRedHill Biopharma Ltd.
0leads
CMPXCompass Therapeutics,…
4leads
6 Total Categories
CATEGORYLEADERvs RDHLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CMPX1/1
Valuation MetricsMultiples, price ratios, and targets
CMPX1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CMPX2/3
Total Returns1Y, 3Y, 5Y total returns with dividends
CMPX5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CMPX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RDHL and CMPX operate at a comparable scale, with $10M and $0 in trailing revenue.
| Metric | RDHLRedHill Biopharma… | CMPXCompass Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $10M | $0 |
| EBITDAEarnings before interest/tax | -$10M | -$74M |
| Net IncomeAfter-tax profit | -$9M | -$68M |
| Free Cash FlowCash after capex | -$8M | -$53M |
| Gross MarginGross profit ÷ Revenue | +64.5% | — |
| Operating MarginEBIT ÷ Revenue | -110.4% | — |
| Net MarginNet income ÷ Revenue | -97.5% | — |
| FCF MarginFCF ÷ Revenue | -86.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +58.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | +16.7% |
CMPX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CMPX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | RDHLRedHill Biopharma… | CMPXCompass Therapeut… |
|---|---|---|
| Market CapShares × price | $5M | $253M |
| Enterprise ValueMkt cap + debt − cash | $903,014 | $232M |
| Trailing P/EPrice ÷ TTM EPS | -0.14x | -4.36x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.64x | — |
| Price / BookPrice ÷ Book value/share | — | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
CMPX leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
CMPX leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
| Metric | RDHLRedHill Biopharma… | CMPXCompass Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | — | -39.7% |
| ROA (TTM)Return on assets | -51.1% | -35.3% |
| ROICReturn on invested capital | — | -41.3% |
| ROCEReturn on capital employed | — | -43.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.05x |
| Net DebtTotal debt minus cash | -$4M | -$21M |
| Cash & Equiv.Liquid assets | $5M | $31M |
| Total DebtShort + long-term debt | $356,000 | $10M |
| Interest CoverageEBIT ÷ Interest expense | -7.99x | — |
CMPX leads this category, winning 2 of 3 comparable metrics.
Total Returns (Dividends Reinvested)
CMPX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CMPX five years ago would be worth $4,067 today (with dividends reinvested), compared to $2 for RDHL. Over the past 12 months, CMPX leads with a +2.8% total return vs RDHL's -49.0%. The 3-year compound annual growth rate (CAGR) favors CMPX at -19.3% vs RDHL's -74.3% — a key indicator of consistent wealth creation.
| Metric | RDHLRedHill Biopharma… | CMPXCompass Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | -1.9% | -64.6% |
| 1-Year ReturnPast 12 months | -49.0% | +2.8% |
| 3-Year ReturnCumulative with dividends | -98.3% | -47.4% |
| 5-Year ReturnCumulative with dividends | -100.0% | -59.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -78.5% |
| CAGR (3Y)Annualised 3-year return | -74.3% | -19.3% |
CMPX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RDHL and CMPX each lead in 1 of 2 comparable metrics.
Risk & Volatility
CMPX is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than RDHL's 1.30 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RDHL currently trades 30.5% from its 52-week high vs CMPX's 26.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RDHLRedHill Biopharma… | CMPXCompass Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.30x | 1.22x |
| 52-Week HighHighest price in past year | $3.31 | $6.88 |
| 52-Week LowLowest price in past year | $0.71 | $1.61 |
| % of 52W HighCurrent price vs 52-week peak | +30.5% | +26.6% |
| RSI (14)Momentum oscillator 0–100 | 60.1 | 23.6 |
| Avg Volume (50D)Average daily shares traded | 39K | 7.7M |
Evenly matched — RDHL and CMPX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | RDHLRedHill Biopharma… | CMPXCompass Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $11.20 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CMPX leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallCompass Therapeutics, Inc. (CMPX)Leads 4 of 6 categories
Loading custom metrics...
RDHL vs CMPX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RDHL or CMPX a better buy right now?
For growth investors, RedHill Biopharma Ltd.
(RDHL) is the stronger pick with 23. 2% revenue growth year-over-year, versus -100. 0% for Compass Therapeutics, Inc. (CMPX). Analysts rate Compass Therapeutics, Inc. (CMPX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RDHL or CMPX?
Over the past 5 years, Compass Therapeutics, Inc.
(CMPX) delivered a total return of -59. 3%, compared to -100. 0% for RedHill Biopharma Ltd. (RDHL). Over 10 years, the gap is even starker: CMPX returned -78. 5% versus RDHL's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RDHL or CMPX?
By beta (market sensitivity over 5 years), Compass Therapeutics, Inc.
(CMPX) is the lower-risk stock at 1. 22β versus RedHill Biopharma Ltd. 's 1. 30β — meaning RDHL is approximately 6% more volatile than CMPX relative to the S&P 500.
04Which is growing faster — RDHL or CMPX?
By revenue growth (latest reported year), RedHill Biopharma Ltd.
(RDHL) is pulling ahead at 23. 2% versus -100. 0% for Compass Therapeutics, Inc. (CMPX). On earnings-per-share growth, the picture is similar: Compass Therapeutics, Inc. grew EPS -16. 7% year-over-year, compared to -115. 2% for RedHill Biopharma Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RDHL or CMPX?
Compass Therapeutics, Inc.
(CMPX) is the more profitable company, earning 0. 0% net margin versus -102. 8% for RedHill Biopharma Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CMPX leads at 0. 0% versus -181. 7% for RDHL. At the gross margin level — before operating expenses — RDHL leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RDHL or CMPX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RDHL or CMPX better for a retirement portfolio?
For long-horizon retirement investors, Compass Therapeutics, Inc.
(CMPX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Both have compounded well over 10 years (CMPX: -78. 5%, RDHL: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RDHL and CMPX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RDHL is a small-cap high-growth stock; CMPX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(RDHL: 58.6% · CMPX: -100.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.